MEDINCELL 2 (EGFF)

signed

The project will support the promoter's research, development and innovation (RDI) activities. Medincell is a biopharmaceutical company offering innovative technologies in drug delivery. Its core business consists in designing long acting formulations of drugs, allowing only one administration of active pharmaceutical ingredients with a therapeutic effect, ranging from a couple of days to many months. The supported RDI nvestments include, among others: i) the screening of pharmaceutical ingredient to be combined with Medincell's proprietary drug delivery system ii) new products formulation iii) the pre-clinical, regulatory and manufacturing development costs of all portfolio candidates, with a focus on early stage programmes to be partnered at clinical stage